| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0001774 | Microglial cell activation | Increases phenotype | PMID:29852196 |
| GO:0004021 | L-alanine:2-oxoglutarate aminotransferase activity | Affects phenotype | PMID:39718591 |
| GO:0005977 | Glycogen metabolic process | Affects phenotype | PMID:39718591 |
| GO:0006641 | Triglyceride metabolic process | Affects phenotype | PMID:32810590; PMID:34273450; PMID:33575850; PMID:34273450; PMID:39718591 |
| GO:0006703 | Estrogen biosynthetic process | Decreases phenotype | PMID:20132345 |
| GO:0006750 | Glutathione biosynthetic process | Decreases phenotype | PMID:29852196 |
| GO:0007033 | Vacuole organization | Increases phenotype | PMID:29852196 |
| GO:0007631 | Feeding behavior | Affects phenotype | PMID:39718591 |
| GO:0008203 | Cholesterol metabolic process | Affects phenotype | PMID:39718591 |
| GO:0008283 | Cell population proliferation | Affects phenotype | PMID:25268938; PMID:25684042 |
| GO:0008542 | Visual learning | Decreases phenotype | PMID:29852196 |
| GO:0015721 | Bile acid and bile salt transport | Decreases phenotype | PMID:36291160 |
| GO:0016042 | Lipid catabolic process | Increases phenotype | PMID:29852196 |
| GO:0019432 | Triglyceride biosynthetic process | Increases phenotype | PMID:30989312 |
| GO:0030199 | Collagen fibril organization | Affects phenotype | PMID:39718591 |
| GO:0030520 | Intracellular estrogen receptor signaling pathway | Affects phenotype | PMID:39365753 |
| GO:0030521 | Androgen receptor signaling pathway | Affects phenotype | PMID:39365753 |
| GO:0035640 | Exploration behavior | Decreases phenotype | PMID:29852196 |
| GO:0040015 | Negative regulation of multicellular organism growth | Increases phenotype | PMID:30392869 |
| GO:0045837 | Negative regulation of membrane potential | Increases phenotype | PMID:36291160 |
| GO:0048598 | Embryonic morphogenesis | Affects phenotype | PMID:28970091 |
| GO:0055007 | Cardiac muscle cell differentiation | Decreases phenotype | PMID:29337257 |
| GO:0061370 | Testosterone biosynthetic process | Decreases phenotype | PMID:20132345; PMID:28743513 |
| GO:0070265 | Necrotic cell death | Increases phenotype | PMID:29852196 |
| GO:0070343 | White fat cell proliferation | Affects phenotype | PMID:39718591 |
| GO:0140042 | Lipid droplet formation | Affects phenotype | PMID:39718591 |
| GO:1901670 | Negative regulation of superoxide dismutase activity | Increases phenotype | PMID:30392869 |
| GO:1903283 | Negative regulation of glutathione peroxidase activity | Increases phenotype | PMID:30392869 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Increases phenotype | PMID:34170130 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.